for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

DBV Technologies SA

DBVT.O

Latest Trade

1.53USD

Change

0.02(+1.32%)

Volume

175,145

Today's Range

1.53

 - 

1.56

52 Week Range

1.51

 - 

13.49

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
1.51
Open
1.56
Volume
175,145
3M AVG Volume
10.84
Today's High
1.56
Today's Low
1.53
52 Week High
13.49
52 Week Low
1.51
Shares Out (MIL)
54.87
Market Cap (MIL)
148.85
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2020 DBV Technologies SA Corporate Sales Release

Latest Developments

More

Dbv Technologies Appoints Sebastien Robitaille To Replace Ramzi Benamar As CFO

DBV Technologies Receives Response From FDA For Viaskin Peanut BLA

DBV Technologies H1 Net Loss Widens To EUR 86.5 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About DBV Technologies SA

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

Industry

Biotechnology & Drugs

Contact Info

177-181 avenue Pierre Brossolette

92120

France

+33.1.55427878

https://www.dbv-technologies.com/

Executive Leadership

Michel de Rosen

Non-Executive Independent Chairman of the Board

Daniel Tasse

Chief Executive Officer, Director

Marie-Catherine Therene

Deputy Chief Executive Officer and Responsible Pharmacist

Sebastien Robitaille

Chief Financial Officer

Caroline Daniere

Chief Human Resource Officer

Key Stats

2.67 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (EUR)

2017

-5.970

2018

-5.740

2019

-4.150

2020(E)

-3.247
Price To Earnings (TTM)
--
Price To Sales (TTM)
10.92
Price To Book (MRQ)
0.66
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
9.47
LT Debt To Equity (MRQ)
7.98
Return on Investment (TTM)
-83.30
Return on Equity (TTM)
-65.93

Latest News

Latest News

U.S. FDA declines to approve DBV Technologies' peanut allergy patch

French drug developer DBV Technologies SA said on Tuesday the U.S. health regulator declined to approve its experimental skin patch for peanut allergy in children, citing concerns about its effectiveness.

BRIEF-DBV Technologies Cash And Cash Equivalents As of March 31 Up At EUR 262.4 Mln

* AS OF MARCH 31, 2020, CASH AND CASH EQUIVALENTS EUR 262.4 MILLION VERSUS EUR 172.0 MILLION AS OF DEC 31, 2019 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-DBV Technologies Provides Update On Viaskin Peanut BLA For Children Ages 4-11 Years

* DBV TECHNOLOGIES PROVIDES UPDATE ON VIASKIN PEANUT BLA FOR CHILDREN AGES 4-11 YEARS

BRIEF-DBV Technologies Announces Partial Exercise Of Underwriters’ Option To Purchase Additional Shares

* ANNOUNCES PARTIAL EXERCISE OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL SHARES IN CONNECTION WITH ITS GLOBAL OFFERING OF ORDINARY SHARES IN THE FORM OF AMERICAN DEPOSITARY SHARES (ADSS)

BRIEF-Dbv Technologies Announces Appointment Of Pascal Wotling As Chief Technical Operations Officer

* DBV TECHNOLOGIES ANNOUNCES APPOINTMENT OF PASCAL WOTLING AS CHIEF TECHNICAL OPERATIONS OFFICER Source text for Eikon: Further company coverage:

BRIEF-DBV Technologies: Potential Long-Term Benefit Of Viaskin Peanut

* ANNOUNCED ON SATURDAY THE COMPANY WILL PRESENT DATA FROM EPICUTANEOUS IMMUNOTHERAPY AT EAACI 2019

BRIEF-DBV Technologies FY Net Loss Widens To 166.1 Million Euros

* REPORTED ON TUESDAY FY SALES AND MARKETING EXPENSES EUR 32.2 MLN VS EUR 15.8 MLN YR AGO

BRIEF-DBV Technologies To Resubmit Biologics License Application For Viaskin Peanut In Q3 2019

* ANNOUNCED ON WEDNESDAY UPDATE ON REGULATORY STATUS OF VIASKIN PEANUT FOR THE TREATMENT OF PEANUT-ALLERGIC CHILDREN 4 TO 11 YEARS OF AGE

BRIEF-DBV Technologies Reports Cash position of 234.5 Million Euros at end March

* CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2018, WERE EUR 234.5 MILLION Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-DBV Technologies: Closing Of Underwriters' Option To Purchase Additional Shares In Global Offering

* REG-DBV TECHNOLOGIES ANNOUNCES CLOSING OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES IN GLOBAL OFFERING

BRIEF-DBV Technologies Announces Pricing Of 122.5 Million Euros Global Offering Of Ordinary Shares

* ANNOUNCES PRICING OF $150.0 MILLION (EUR 122.5 MILLION) GLOBAL OFFERING OF ORDINARY SHARES

BRIEF-DBV Technologies ‍Announces Intention To Issue And Sell Up To $150 Mln Of New Ordinary Shares​

* DBV TECHNOLOGIES ANNOUNCES THE LAUNCH OF A PROPOSED GLOBAL OFFERING OF ORDINARY SHARES, WHICH MAY BE IN THE FORM OF AMERICAN DEPOSITARY SHARES

BRIEF-DBV Technologies FY Net Loss widens to 147.7 Million Euros

* CASH AND CASH EQUIVALENTS AS OF DEC 31, 2017 EUR 137.9 MILLION VERSUS EUR 256.5 MILLION YEAR AGO

BRIEF-DBV Technologies Announces Result From Phase II Study of Viaskin Milk

* ANNOUNCED ON MONDAY, RESULT FROM PHASE II STUDY OF VIASKIN MILK IN MILK-ALLERGIC PATIENTS

BRIEF-DBV Technologies Announces Results From Phase II Study Of Viaskin Milk In Milk-Allergic Patients

* DBV TECHNOLOGIES ANNOUNCES RESULTS FROM PHASE II STUDY OF VIASKIN MILK IN MILK-ALLERGIC PATIENTS

BRIEF-DBV Technologies Cash And Cash Equivalents At Dec. 31 Down At 137.9 Million Euros

* CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2017, WERE EUR 137.9 MILLION, VERSUS EUR 256.5 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Reg-Dbv Technologies Provides Update On Regulatory Progress For Viaskin Peanut

* REG-DBV TECHNOLOGIES PROVIDES UPDATE ON REGULATORY PROGRESS FOR VIASKIN PEANUT

BRIEF-DBV Technologies ‍announces positive data from Phase IIb trial and long-term study of Viaskin Peanut​

* ANNOUNCES PUBLICATION OF POSITIVE DATA FROM PHASE IIB TRIAL AND LONG-TERM STUDY OF VIASKIN PEANUT

BRIEF-DBV Technologies reports at Sept. 30 cash position of 170.5 million euros

* CASH POSITION AT SEPT. 30, 2017 EUR 170.5 MILLION VERSUS EUR 256.5 MILLION AT DEC. 31, 2016 Source text: http://bit.ly/2htbI61 Further company coverage: (Gdynia Newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up